Biotechnology (Over 45,000 results)

Hardback. Condition: Very Good. Advances in medicine have made possible better treatments for widespread, familiar human illnesses like cancer, diabetes, and heart disease. Yet there are thousands of much less common diseases, most of genetic origin, each classed as rare because it afflicts only a small number of people. These patient groups were long ignored by a pharmaceutical industry that judged them too small to provide a return on the investment needed to develop an effective remedy. Yet these orphaned diseases collectively caused misery and expense, often far greater than did more common ailments, for tens of millions of individuals and their families. Forty years ago, a revolution that transformed the prospects of patients with rare diseases was lit by three sparks. The passage of the 1983 U.S. Orphan Drug Act resulted from public pressure brought by rare disease patients, their families, and advocates. The AIDS epidemic triggered additional activism, compounded when patients with the rare disease hemophilia became HIV-positive after infusion of tainted blood products. And the third spark was the emergence in the early 1980s of biotechnology companies like Genentech, Amgen, and Biogen employing then-new genetic engineering instead of conventional approaches to pharmaceutical development. Soon after, Genzyme became the first company to develop a treatment for a rare genetic disorder, Gaucher disease, which would come to transform the industry. Jim Geraghty has been a passionate participant in the orphan drug revolution since its inception--a leader in the field as a strategy consultant, biotechnology executive, and venture entrepreneur. His book is in part a history, with eyewitness accounts of advances as they occurred and portraits of the pioneering scientists and physicians, tireless activists, and visionary business leaders who made the revolution happen. And it tells deeply personal stories of patients and parents willing to risk new, untried therapies. But Geraghty also uses his exceptional experience and vantage point to look forward to the immense promise of the newest technologies like gene therapy and gene editing for the treatment of patients today and tomorrow. He concludes with thoughtful consideration of important questions. Why do drugs to treat orphan diseases cost so much? How can we ensure they are affordable? How can their effectiveness be responsibly assessed? And how can access to them be expanded internationally? This book graphically and poignantly illustrates how far an important healthcare revolution has come and reminds us that if not nurtured, it could end before its immense promise has been fulfilled.…

Condition: As New. Shows minimal signs of wear and previous use. Can include minimal notes/highlighting. A portion of your purchase benefits nonprofits! - Note: Edition & format may differ from what is shown in stock photo & item details. May not include supplementary material (toys, access code, dvds, etc). …

Paperback. Condition: Good.

Paperback. Condition: Good. The world's food production is undergoing a rapid and revolutionary transformation, but little is known about it and less is being done to question the wisdom of it. Within a very few years, much of what we eat will have been genetically engineered, without proper consideration of the issues of public health, consumer choice and ecological stability. Against the Grain argues that the consequences of this huge experiment could be catastrophic, and at the very least have been underestimated or ignored by the industries exploiting the new technologies. The authors have unearthed government and industry documents which show these new methods to be far from fail-safe or risk free. Comprehensively supported with facts and references, the book provides a full account of the science and technologies involved in producing 'transgenic plants'. It also explains the scale and speed of what is going on, and argues for full public accountability and control of new developments - before it is too late.…

Paperback. Condition: Good. Argues that ensuring safe food involves more than washing hands or cooking food to higher temperatures. This book demonstrates how powerful food industries oppose safety regulations, deny accountability, and blame consumers when something goes wrong, and how century-old laws for ensuring food safety no longer protect our food supply.…

Paperback. Condition: Fair. Argues that ensuring safe food involves more than washing hands or cooking food to higher temperatures. This book demonstrates how powerful food industries oppose safety regulations, deny accountability, and blame consumers when something goes wrong, and how century-old laws for ensuring food safety no longer protect our food supply.…

Condition: very_good. Book is in very good condition and may include minimal underlining highlighting. The book can also include "From the library of" labels. May not contain miscellaneous items toys, dvds, etc. . We offer 100% money back guarantee and 24 7 customer service.

Condition: very_good. Book is in very good condition and may include minimal underlining highlighting. The book can also include "From the library of" labels. May not contain miscellaneous items toys, dvds, etc. . We offer 100% money back guarantee and 24 7 customer service.

Condition: very_good. Book is in very good condition and may include minimal underlining highlighting. The book can also include "From the library of" labels. May not contain miscellaneous items toys, dvds, etc. . We offer 100% money back guarantee and 24 7 customer service.

Condition: acceptable. Book is in acceptable condition and shows signs of wear. Book may also include underlining highlighting. The book can also include "From the library of" labels. May not contain miscellaneous items toys, dvds, etc. . We offer 100% money back guarantee and 24 7 customer service.

Paperback. Condition: Very Good. 1. It's a well-cared-for item that has seen limited use. The item may show minor signs of wear. All the text is legible, with all pages included. It may have slight markings and/or highlighting.

Paperback. Condition: Very Good. If you investigate biological systems and might use mass spectrometry in your research but need to know more about it, this book is for you. It introduces the fundamental concepts of mass spectrometry and how mass spectrometers work. It also presents recent advancements particularly interesting to bio-researchers in an easy-to-understand manner that does not require extensive background in chemistry, math, or physics.…

paperback. Condition: Good.

Condition: very_good. Book is in very good condition and may include minimal underlining highlighting. The book can also include "From the library of" labels. May not contain miscellaneous items toys, dvds, etc. . We offer 100% money back guarantee and 24 7 customer service.

Condition: very_good. Fast Free Shipping â" Very Good condition book with a firm cover and clean pages. Shows normal use and some light wear or limited notes markings. A solid, nice copy to enjoy.

Paperback. Condition: Good. Thoroughly updated with practical information on the latest developments in the biotechnology field, this popular text provides the tools, practice, and basic knowledge for success in the biotech workforce. With its balanced coverage of basic cell and molecular biology, fundamental techniques, historical accounts, and hands-on applications, the Second Edition emphasizes the relevance of biotechnology in agriculture, medicine, and industry. Special sections on ethical and environmental issues in biotechnology, career profiles, and research ?tools? are also highlighted in the book. The Second Edition features a thoroughly revised chapter on ethics. …

paperback. Condition: Very Good. Fast shipping and order satisfaction guaranteed. A portion of your purchase benefits Non-Profit Organizations, First Aid and Fire Stations.

hardcover. Condition: Good. Fast shipping and order satisfaction guaranteed. A portion of your purchase benefits Non-Profit Organizations, First Aid and Fire Stations.

paperback. Condition: Good. There is light highlighting or handwriting through out the book. Fast shipping and order satisfaction guaranteed. A portion of your purchase benefits Non-Profit Organizations, First Aid and Fire Stations.

Paperback. Condition: Good. Visit our website for sample chapters.

Condition: Good. . No Dust Jacket. All orders guaranteed and ship within 24 hours. Before placing your order for please contact us for confirmation on the book's binding. Check out our other listings to add to your order for discounted shipping.

Paperback. Condition: Very Good. A comprehensive overview of the new business context for biopharma companies, featuring numerous case studies and state-of-the-art marketing models  Biotechnology has developed into a key innovation driver especially in the field of human healthcare. But as the biopharma industry continues to grow and expand its reach, development costs are colliding with aging demographics and cost-containment policies of private and public payers. Concurrently, the development and increased affordability of sophisticated digital technologies has fundamentally altered many industries including healthcare. The arrival of new information technology (infotech) companies on the healthcare scene presents both opportunities and challenges for the biopharma business model. To capitalize on new digital technologies from R&D through commercialization requires industry leaders to adopt new business models, develop new digital and data capabilities, and partner with innovators and payers worldwide. Written by two experts, both of whom have had decades of experience in the field, this book provides a comprehensive overview of the new business context and marketing models for biotech companies. Informed by extensive input by senior biotech executives and leading consultancies serving the industry, it analyzes the strategies and key success factors for the financing, development, and commercialization of novel therapeutic products, including strategies for engagement with patients, physicians and healthcare payers. Throughout case studies provide researchers, corporate marketers, senior managers, consultants, financial analysts, and other professionals involved in the biotech sector with insights, ideas, and models.   JACQUALYN FOUSE, PhD, RETIRED PRESIDENT AND CHIEF OPERATING OFFICER, CELGENE ?Biotech companies have long been innovators, using the latest technologies to enable cutting edge science to help patients with serious diseases. This book is essential to help biotech firms understand how they can?and must?apply the newest technologies including disruptive ones, alongside science, to innovate and bring new value to the healthcare system.? BRUCE DARROW, MD, PhD, CHIEF MEDICAL INFORMATION OFFICER, MOUNT SINAI HEALTH SYSTEM ?Simon and Giovannetti have written an essential user?s manual explaining the complicated interplay of the patients who deserve cutting-edge medical care, the biotechnology companies (big and small) creating the breakthroughs, and the healthcare organizations and clinicians who bridge those worlds.? EMMANUEL BLIN, FORMER CHIEF STRATEGY OFFICER AND SENIOR VICE PRESIDENT, BRISTOL-MYERS SQUIBB ?If you want to know where biopharma is going, read this book! Our industry is facing unprecedented opportunities driven by major scientific breakthroughs, while transforming itself to address accelerated landscape changes driven by digital revolutions and the emergence of value-based healthcare worldwide. In this ever-changing context, we all need to focus everything we do on the patients. They are why we exist as an industry, and this is ultimately what this insightful essay is really about.?  JOHN MARAGANORE, PRESIDENT AND CHIEF EXECUTIVE OFFICER, ALNYLAM PHARMACEUTICALS ?Since the mapping of the human genome was completed nearly 15 years ago, the biotechnology industry has led the rapid translation of raw science to today?s innovative medicines. However, the work does not stop in the lab. Delivering these novel medicines to patients is a complex and multifaceted process, which is elegantly described in this new book..…

Paperback. Condition: Good. A comprehensive overview of the new business context for biopharma companies, featuring numerous case studies and state-of-the-art marketing models  Biotechnology has developed into a key innovation driver especially in the field of human healthcare. But as the biopharma industry continues to grow and expand its reach, development costs are colliding with aging demographics and cost-containment policies of private and public payers. Concurrently, the development and increased affordability of sophisticated digital technologies has fundamentally altered many industries including healthcare. The arrival of new information technology (infotech) companies on the healthcare scene presents both opportunities and challenges for the biopharma business model. To capitalize on new digital technologies from R&D through commercialization requires industry leaders to adopt new business models, develop new digital and data capabilities, and partner with innovators and payers worldwide. Written by two experts, both of whom have had decades of experience in the field, this book provides a comprehensive overview of the new business context and marketing models for biotech companies. Informed by extensive input by senior biotech executives and leading consultancies serving the industry, it analyzes the strategies and key success factors for the financing, development, and commercialization of novel therapeutic products, including strategies for engagement with patients, physicians and healthcare payers. Throughout case studies provide researchers, corporate marketers, senior managers, consultants, financial analysts, and other professionals involved in the biotech sector with insights, ideas, and models.   JACQUALYN FOUSE, PhD, RETIRED PRESIDENT AND CHIEF OPERATING OFFICER, CELGENE ?Biotech companies have long been innovators, using the latest technologies to enable cutting edge science to help patients with serious diseases. This book is essential to help biotech firms understand how they can?and must?apply the newest technologies including disruptive ones, alongside science, to innovate and bring new value to the healthcare system.? BRUCE DARROW, MD, PhD, CHIEF MEDICAL INFORMATION OFFICER, MOUNT SINAI HEALTH SYSTEM ?Simon and Giovannetti have written an essential user?s manual explaining the complicated interplay of the patients who deserve cutting-edge medical care, the biotechnology companies (big and small) creating the breakthroughs, and the healthcare organizations and clinicians who bridge those worlds.? EMMANUEL BLIN, FORMER CHIEF STRATEGY OFFICER AND SENIOR VICE PRESIDENT, BRISTOL-MYERS SQUIBB ?If you want to know where biopharma is going, read this book! Our industry is facing unprecedented opportunities driven by major scientific breakthroughs, while transforming itself to address accelerated landscape changes driven by digital revolutions and the emergence of value-based healthcare worldwide. In this ever-changing context, we all need to focus everything we do on the patients. They are why we exist as an industry, and this is ultimately what this insightful essay is really about.?  JOHN MARAGANORE, PRESIDENT AND CHIEF EXECUTIVE OFFICER, ALNYLAM PHARMACEUTICALS ?Since the mapping of the human genome was completed nearly 15 years ago, the biotechnology industry has led the rapid translation of raw science to today?s innovative medicines. However, the work does not stop in the lab. Delivering these novel medicines to patients is a complex and multifaceted process, which is elegantly described in this new book..…

Paperback. Condition: Very Good. A decade after his now-famous pronouncement of the end of history, Francis Fukuyama argues that as a result of biomedical advances, we are facing the possibility of a future in which our humanity itself will be altered beyond recognition. Fukuyama sketches a brief history of man's changing understanding of human nature: from Plato and Aristotle to the modernity's utopians and dictators who sought to remake mankind for ideological ends. Fukuyama argues that the ability to manipulate the DNA of all of one person's descendants will have profound, and potentially terrible, consequences for our political order, even if undertaken with the best of intentions. In Our Posthuman Future, one of our greatest social philosophers begins to describe the potential effects of genetic exploration on the foundation of liberal democracy: the belief that human beings are equal by nature.…

Paperback. Condition: Good. A decade after his now-famous pronouncement of the end of history, Francis Fukuyama argues that as a result of biomedical advances, we are facing the possibility of a future in which our humanity itself will be altered beyond recognition. Fukuyama sketches a brief history of man's changing understanding of human nature: from Plato and Aristotle to the modernity's utopians and dictators who sought to remake mankind for ideological ends. Fukuyama argues that the ability to manipulate the DNA of all of one person's descendants will have profound, and potentially terrible, consequences for our political order, even if undertaken with the best of intentions. In Our Posthuman Future, one of our greatest social philosophers begins to describe the potential effects of genetic exploration on the foundation of liberal democracy: the belief that human beings are equal by nature.…

Paperback. Condition: Fair. A decade after his now-famous pronouncement of the end of history, Francis Fukuyama argues that as a result of biomedical advances, we are facing the possibility of a future in which our humanity itself will be altered beyond recognition. Fukuyama sketches a brief history of man's changing understanding of human nature: from Plato and Aristotle to the modernity's utopians and dictators who sought to remake mankind for ideological ends. Fukuyama argues that the ability to manipulate the DNA of all of one person's descendants will have profound, and potentially terrible, consequences for our political order, even if undertaken with the best of intentions. In Our Posthuman Future, one of our greatest social philosophers begins to describe the potential effects of genetic exploration on the foundation of liberal democracy: the belief that human beings are equal by nature.…

Paperback. Condition: Good. Reprint. It's a preowned item in good condition and includes all the pages. It may have some general signs of wear and tear, such as markings, highlighting, slight damage to the cover, minimal wear to the binding, etc., but they will not affect the overall reading experience. Ex-Library.…

Condition: Very Good. [ No Hassle 30 Day Returns ][ Ships Daily ] [ Underlining/Highlighting: NONE ] [ Writing: NONE ] [ Edition: First ] Publisher: Holt, Rinehart & Winston Pub Date: 1/1/1998 Binding: Paperback Pages: 66 First edition.

hardcover. Condition: Very Good.

hardcover. Condition: Very Good.